Media Availability — August 10 – 24, 2015
Monday, August 10, 2015, 11:00 a.m. EDT
(919) 541 - 5143
New research published online August 10 in the journal Nature Genetics found that a mutation-causing enzyme known as APOBEC3A (A3A) may be the main cause of mutations in certain cancers. Previous work from other groups implicated another APOBEC enzyme, known as APOBEC3B (A3B).
Corresponding author Dmitry Gordenin, Ph.D., head of the NIEHS Mechanisms of Genome Dynamics Group, will be available for interviews on this new finding Monday, August 10 through Monday, August 24.
APOBEC proteins perform an important function in the immune system, by restricting the spread of viruses within the body. However, a subset of these proteins produces the majority of DNA mutations in certain cancers, according to a team led by researchers at the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health. The scientists previously found that APOBEC enzymes were responsible for a substantial number of mutations in 80-90 percent of bladder and cervical cancers, and 20-30 percent of head and neck, breast, and lung cancers.
In this new study, NIEHS scientists went further by engineering two varieties of yeast. One strain produced APOBEC3A (A3A) and the other produced A3B. Once team members identified the DNA sequences that each APOBEC preferentially mutated in yeast, they used the findings to mine data from The Cancer Genome Atlas, a cancer database funded and managed by the National Cancer Institute and the National Human Genome Research Institute.
The study concluded that in cancer samples with a high number of APOBEC-induced mutations, A3A caused 10 times as many DNA sequence changes than A3B. In samples with small numbers of APOBEC mutations, A3B was responsible. The results could have far-reaching implications for diagnosis and personalized treatment of cancers.
These discoveries were made, in part, using an analytical package developed by the NIEHS Integrative Bioinformatics Support Group led by David Fargo, Ph.D.
This video, produced by Research Square in collaboration with Nature Publishing Group, depicts the findings of this research. https://youtu.be/PgTxhUKqwmc
Reference: Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA. 2015. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet; doi: 10.1038/ng.3378 [Online 10 August 2015]. [Abstract Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA. 2015. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet; doi: 10.1038/ng.3378 [Online 10 August 2015].]
NIEHS supports research to understand the effects of the environment on human health and is part of NIH. For more information on environmental health topics, visit http://www.niehs.nih.gov. Subscribe to one or more of the NIEHS news lists (NIEHS Newsroom Releases) to stay current on NIEHS news, press releases, grant opportunities, training, events, and publications.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health®